TY - JOUR
T1 - Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases
AU - Del Pozo, Victoria
AU - Bobolea, Irina
AU - Rial, Manuel J.
AU - Espigol Frigolé, Georgina
AU - Solans, Roser
AU - Hernández Rivas, Jesús María
AU - Mora, Elvira
AU - Crespo Lessmann, Astrid
AU - Izquierdo Alonso, José Luis
AU - Domínguez Sosa, María Sandra
AU - Maza Solano, Juan
AU - Atienza-Mateo, Belén
AU - Bañas-Conejero, David
AU - Moure, Abraham L.
AU - Rua Figueroa, Íñigo
PY - 2024/1/5
Y1 - 2024/1/5
N2 - Eosinophil-related diseases represent a group of pathologic conditions with highly heterogeneous clinical presentation and symptoms ranging from mild to critical. Both systemic and localized forms of disease are typically treated with glucocorticoids. The approval of novel biologic therapies targeting the interleukin-5 pathway can help reduce the use of systemic glucocorticoids (SGC) in eosinophilic diseases and reduce the risk of SGC-related adverse effects (AEs). In this article, a panel of experts from different medical specialties reviewed current evidence on the use of SGC in two systemic eosinophilic diseases: Eosinophilic Granulomatosis with PolyAngiitis (EGPA) and HyperEosinophilic Syndrome (HES); and in two single-organ (respiratory) eosinophilic diseases: Chronic RhinoSinusitis with Nasal Polyps (CRSwNP) and Severe Asthma with Eosinophil Phenotype (SA-EP), and contrasted it with their experience in clinical practice. Using nominal group technique, they reached consensus on key aspects related to the dose and tapering of SGC as well as on the initiation of biologics as SGC-sparing agents. Early treatment with biologics could help prevent AEs associated with medium and long-term use of SGC.
AB - Eosinophil-related diseases represent a group of pathologic conditions with highly heterogeneous clinical presentation and symptoms ranging from mild to critical. Both systemic and localized forms of disease are typically treated with glucocorticoids. The approval of novel biologic therapies targeting the interleukin-5 pathway can help reduce the use of systemic glucocorticoids (SGC) in eosinophilic diseases and reduce the risk of SGC-related adverse effects (AEs). In this article, a panel of experts from different medical specialties reviewed current evidence on the use of SGC in two systemic eosinophilic diseases: Eosinophilic Granulomatosis with PolyAngiitis (EGPA) and HyperEosinophilic Syndrome (HES); and in two single-organ (respiratory) eosinophilic diseases: Chronic RhinoSinusitis with Nasal Polyps (CRSwNP) and Severe Asthma with Eosinophil Phenotype (SA-EP), and contrasted it with their experience in clinical practice. Using nominal group technique, they reached consensus on key aspects related to the dose and tapering of SGC as well as on the initiation of biologics as SGC-sparing agents. Early treatment with biologics could help prevent AEs associated with medium and long-term use of SGC.
KW - Adverse events
KW - Eosinophilic diseases
KW - Systemic glucocorticoids
KW - Biologics
KW - Tapering
KW - Treatment optimisation
UR - http://www.scopus.com/inward/record.url?scp=85183083044&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/3d3b36d0-63a9-345a-b6d5-494703627575/
U2 - 10.3389/fimmu.2023.1310211
DO - 10.3389/fimmu.2023.1310211
M3 - Review article
C2 - 38250075
SN - 1664-3224
VL - 14
JO - Frontiers in Immunology
JF - Frontiers in Immunology
M1 - 1310211
ER -